An observational study to describe the effectiveness, safety, and patient-reported outcomes (PROs) in participants with moderate to severe active rheumatoid arthritis (RA) in France receiving filgotinib in real-world setting.

Inclusion Criteria:

• Participants aged ≥18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local treatment practices and product label for the first time.
• Female participants of childbearing potential must agree to use contraception while taking filgotinib as per product label.
• Participants must be willing and able to use an electronic device to complete the study PROs.
• Participant must sign and date the Informed Consent Form (ICF) before enrollment into the study.

Exclusion Criteria:

• Participation in any interventional or non-interventional study without prior approval from the Medical Lead. This does not preclude inclusion of participants enrolled to national registries.
• Female participant is pregnant or intending to become pregnant while taking filgotinib.

The study population will consist of participants aged ≥ 18 years with moderate to severe active RA receiving filgotinib who will be enrolled in France.